Chikungunya
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Bavarian NordicChikungunya
Gylden PharmaPepGNP-ChikV
Clinical Trials (2)
Total enrollment: 100 patients across 2 trials
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Start: Nov 2019Est. completion: Jan 202160 patients
Phase 2Completed
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
Start: Aug 2026Est. completion: May 202840 patients
Phase 1Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space